Neupro

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2016
01220062016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
OBJECTIVE A new and unique methodology was developed to evaluate the association between periodic limb movements (PLMs) and… (More)
Is this relevant?
2015
2015
BACKGROUND Rotigotine is a potent and selective D1, D2, and D3 dopaminergic receptor agonist. Due to an extensive first-pass… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
Review
2014
Review
2014
Restless leg syndrome (RLS), also known as Willis-Ekbom disease, is a condition that includes sensations such as crawling… (More)
Is this relevant?
2011
2011
re ductions in the International Restless Legs Syndrome Rating Scale sum scores by 2.09 to 2.55 points compared with a reduction… (More)
Is this relevant?
Review
2010
Review
2010
Rotigotine (Neupro) is a non-ergolinic dopamine agonist available as a transdermal patch that can be applied once daily. To date… (More)
Is this relevant?
2008
2008
A transdermal patch formulation of the non-ergolinic dopamine receptor agonist rotigotine (Neupro) is indicated for use as… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND In patients experiencing motor fluctuations, a major treatment challenge is the reduction of "off" time, particularly… (More)
Is this relevant?
Review
2007
Review
2007
A transdermal patch formulation of the non-ergolinic dopamine agonist rotigotine (Neupro) is indicated for use as monotherapy in… (More)
Is this relevant?
2006
2006
OBJECTIVE Rotigotine (Neupro) is formulated as a transdermal delivery system designed to provide a selective, non-ergot D3/D2/D1… (More)
Is this relevant?
Review
2006
Review
2006
Fluctuations (wearing-off, on off phenomenon, dyskinesias) are a big challenge in the long term treatment of parkinsonian… (More)
Is this relevant?